David Liu (courtesy Broad Institute)

David Li­u's biotech shoots for $150M+ IPO raise to de­vel­op CRISPR 3.0

Last quar­ter’s biotech IPO raise was the low­est in five years, but the team at Prime Med­i­cine thinks their “holy crap” gene edit­ing tech­nol­o­gy can break the spell.

The Cam­bridge, MA-based com­pa­ny, found­ed by Har­vard bi­ol­o­gist and gene edit­ing pi­o­neer David Liu, pen­ciled in a $151 mil­lion raise on Thurs­day, set­ting the terms for an 8.9 mil­lion-share of­fer­ing at a range of $16 to $18. At the mid­point, the pre­clin­i­cal start­up would be worth $1.7 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.